Qingyihuaji Optimized Formula
Pancreatic Neoplasms
Fudan UniversityPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 81/ 100
Competitive context
381 Active assets in the Pancreatic Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tinzaparin Helsinki University Central Hospital | Phase 4 | BBB |
Eloxatin Memorial Sloan Kettering Cancer Center | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Taiho Oncology, Inc. | Phase 3 | BB |
FLUOROURACILUM Memorial Sloan Kettering Cancer Center | Phase 3 | BB |
Capecitabine Tianjin Medical University Cancer Institute and Hospital | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →